Duality of Antidepressants and Neuroprotectants
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The co-morbidity of neuropsychiatric disorders, particularly major depressive disorder (MDD) with neurodegenerative diseases, in particular Parkinson’s disease (PD) is now well recognized. Indeed, it is suggested that depressive disorders, especially in late life, may be an indication of latent neurodegeneration. Thus, it is not unreasonable to expect that deterrents of MDD may also deter the onset and/or progression of the neurodegenerative diseases including PD. In this review, examples of neuroprotective efficacy of established as well as prospective antidepressants are provided. Conversely, mood-regulating effects of some neuroprotective drugs are also presented. Thus, in addition to currently used antidepressants, ketamine, nicotine, curcumin, and resveratrol are discussed for their dual efficacy. In addition, potential neurobiological substrates for their actions are presented. It is concluded that pharmacological developments of mood-regulating or neuroprotective drugs can have cross benefit in co-morbid conditions of neuropsychiatric and neurodegenerative disorders and that inflammatory and neurotrophic factors play important roles in both conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“In addition, using conditional knockout mice, it was deducted that BDNF is required for the antidepressant-like effect of ketamine (Autry et al. 2011).”
BackgroundInfluentialThe Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450 · cited 4×
“In this regard, it has been suggested that addition of piperine could enhance curcumin’s absorption (Hamaguchi et al. 2010).”
BackgroundInfluentialNeurobiology of chronic mild stress: parallels to major depression
Hill, M. N., Hellemans, K. G. C., Verma, P., Gorzalka, B. B., & Weinberg, J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.001 · Cited by 420 · cited 2×
“Major depression is manifested by a combination of symptoms that interfere with the ability to work, sleep, eat, and enjoy once pleasurable activities.”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346 · cited 2×
“Interestingly, ketamine’s antidepressant effect requires activation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, as NBQX, an AMPA receptor antagonist, can block ketamine’s effects (Maeng et al. 2008; Koike et al. 2011).”
BackgroundHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Duman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223 · cited 2×
“prevent formation of amyloid plaques in transgenic mouse model as well as in humans (Sheline et al. 2014).”
BackgroundCurcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.001 · Cited by 216
Antidepressant effects of nicotine in an animal model of depression
Tizabi, Y., Overstreet, D. H., Rezvani, A. H., Louis, V. A., Clark Jr, E., Janowsky, D. S., & Kling, M. A. (1999) · Psychopharmacology · doi:10.1007/s002130050879 · Cited by 209 · cited 1×
“A number of preclinical (Semba et al. 1998; Djuric et al. 1999; Tizabi et al. 1999, 2000, 2009, 2010; Kalejaiye et al. 2013) as well as a limited number of clinical studies (Pomerleau and Pomerleau 1992; Salin-Pascual et al. 1995; McClernon et al. 2006; Cook et al. 2007) have verified…”
BackgroundSelf-citationIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201 · cited 4×
“…et al. 2000; Zarate et al. 2006; Iadarola et al. 2015), and that a single sub-anesthetic dose of ketamine has rapid and sus- tained antidepressant effects in treatment-resistant patients suffering from major depressive disorder (Maeng et al. 2008; Iadarola et al. 2015; Kavalali and Monteggia 2015).”
BackgroundInfluentialNeuronal network plasticity and recovery from depression
Castrén, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1 · Cited by 190
Is impaired neurogenesis relevant to the affective symptoms of depression?
Sapolsky, R. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.012 · Cited by 188
Xu, H., Steven Richardson, J., & Li, X.-M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300009 · Cited by 167 · cited 2×
“A number of earlier reports indicated neurotrophic effects of antidepressants, reflected in elevated levels of brain- derived neurotrophic factor (BDNF), particularly in the hippocampus, suggesting possible neuroprotective effects as well (Nestler et al. 2002; Xu et al. 2003).”
BackgroundPicciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157 · cited 2×
“Thus, sufficient evidence for applicability of nicotine or nicotinic compounds in neuropsychiatric disorders including post- traumatic stress disorder and MDD has been recently provided (Barreto et al. 2015; Picciotto et al. 2015; Rah- man 2015).”
BackgroundLiu, D., Wang, Z., Gao, Z., Xie, K., Zhang, Q., Jiang, H., & Pang, Q. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.068 · Cited by 151
O'Sullivan, J. B., Ryan, K. M., Curtin, N. M., Harkin, A., & Connor, T. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570800967x · Cited by 146
Ali, S. H., Madhana, R. M., K.V., A., Kasala, E. R., Bodduluru, L. N., Pitta, S., Mahareddy, J. R., & Lahkar, M. (2015) · Steroids · doi:10.1016/j.steroids.2015.05.010 · Cited by 145 · cited 4×
“Moreover, in both cases, the antidepressant effect of resveratrol was associated with an increase in hippocampal BDNF (Hurley et al. 2014; Ali et al. 2015).”
BackgroundInfluentialAntidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats
Semba, J., Mataki, C., Yamada, S., Nankai, M., & Toru, M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00477-0 · Cited by 140
Effects of transderman nicotine on mood and sleep in nonsmoking major depresssed patients
Salín-Pascual, R. J., Galicia-Polo, L., Drucker-Colín, R., de la Fuente, J. R., Drucker-Colín, R., & Salín-Pascual, R. J. (1995) · Psychopharmacology · doi:10.1007/bf02246496 · Cited by 113 · cited 2×
“…(Semba et al. 1998; Djuric et al. 1999; Tizabi et al. 1999, 2000, 2009, 2010; Kalejaiye et al. 2013) as well as a limited number of clinical studies (Pomerleau and Pomerleau 1992; Salin-Pascual et al. 1995; McClernon et al. 2006; Cook et al. 2007) have verified an antidepressant effect of nicotine.”
BackgroundMcClernon, F. J., Hiott, F. B., Westman, E. C., Rose, J. E., & Levin, E. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0516-y · Cited by 106
Antidepressant Effect of Ingested Nicotine in Female Rats of Flinders Resistant and Sensitive Lines
Djurić, V. J., Dunn, E., Overstreet, D. H., Dragomir, A., & Steiner, M. (1999) · Physiology & Behavior · doi:10.1016/s0031-9384(99)00091-8 · Cited by 79
Depressive Characteristics of FSL Rats
Tizabi, Y., Rezvani, A. H., Russell, L. T., Tyler, K. Y., & Overstreet, D. H. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00236-7 · Cited by 70 · cited 1×
“A number of preclinical (Semba et al. 1998; Djuric et al. 1999; Tizabi et al. 1999, 2000, 2009, 2010; Kalejaiye et al. 2013) as well as a limited number of clinical studies (Pomerleau and Pomerleau 1992; Salin-Pascual et al. 1995; McClernon et al. 2006; Cook et al. 2007) have verified…”
BackgroundSelf-citation
Cited by
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172
Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Li, Y., Ailing, H., & Jian, P. (2019) · Radiation Research · doi:10.1667/rr15171.1 · Cited by 5
Metadata
- Authors
- Tizabi, Y.
- Venue
- Neurotoxicity Research
- Published
- 2015-11-27
- Volume
- 30
- Issue
- 1
- Pages
- 1-13
- ISSN
- 1029-8428 (ISSN-L)
- 1476-3524
- OpenAlex
- W2180749160
- Cited by
- 48
- References
- 30
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.